MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30, TRML had $917K increase in cash & cash equivalents over the period. -$41,959K in free cash flow.

Cash Flow Overview

Change in Cash
$917K
Free Cash flow
-$41,959K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-06-30
Net loss
-46,062
Stock-based compensation expense
4,739
Realized gain on investments
0
Non-cash lease expense
86
Prepaid expenses and other current assets
-670
Other non-current assets
-618
Operating lease liabilities
-99
Accrued expenses and other current liabilities
1,687
Accounts payable
-609
Depreciation on property and equipment
24
Accretion of discount on investments
2,997
Net cash used in operating activities
-41,943
Maturities of investments
167,878
Purchases of property and equipment
16
Purchases of investments
125,618
Net cash provided by (used in) investing activities
42,244
Proceeds from exercise of stock options
623
Proceeds from public offering of common stock, net of issuance costs
0
Repurchase of common stock originally issued upon early exercise of stock options
7
Net cash provided by financing activities
616
Net increase (decrease) in cash, cash equivalents and restricted cash
917
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Tourmaline Bio, Inc. (TRML)

Tourmaline Bio, Inc. (TRML)